ArticleScientific reports2025
Identifying SUMOylation-related genes in liver fibrosis with bioinformatics and experimental models for diagnostic insights.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Liver fibrosis (LF) is a medical disorder caused by prolonged chronic liver injury, which, if left untreated, can progress to cirrhosis or liver cancer, posing significant risks to patient health. In recent years, the increase in liver diseases, including alcoholic liver disease, non-alcoholic fatty liver disease, and viral hepatitis, has significantly heightened the prevalence of LF. SUMOylation, an important post-translational modification, is essential for regulating cellular functions and may play a critical role in the progression of LF; however, its exact mechanisms remain poorly understood. This study conducted a thorough examination of the expression patterns of SUMOylation-related genes in patients with LF for the first time. We obtained two LF datasets (GSE130970 and GSE84044) from the GEO database, integrated the data for DEG analysis and functional enrichment analysis, and employed machine learning techniques to identify pivotal genes. Furthermore, we utilized ssGSEA and immune cell infiltration analysis to evaluate the roles of these genes within the immunological context of LF. To validate the bioinformatics findings, we established a CCl₄-induced C57BL/6 mouse model of LF to investigate the expression of relevant genes. A total of 1,583 differentially expressed genes were identified, 13 of which were associated with SUMOylation. These genes were primarily enriched in biological processes related to cell signal transduction, cell adhesion, and inflammatory responses. Utilizing machine learning approaches, we found eight crucial genes (NR3C2, PCNA, THRB, CDKN2A, DNMT1, MDM2, SMC6, and RXRA) that have significant diagnostic potential in the progression of LF. Additionally, we observed a significant increase in the infiltration of several immune cell types, with evident correlations between the expression of SUMOylation-related genes and specific immune cell types. The results of the animal experiments validated the bioinformatics analysis, as key SUMOylation-related genes exhibited expression patterns consistent with our expectations in the CCl₄-induced LF mouse model. This study elucidates the critical roles of SUMOylation-related genes in LF, highlighting their influence on liver damage and the progression of fibrosis through the regulation of cytokine synthesis, facilitation of hepatic stellate cell activation, and enhancement of immune cell infiltration. The identified significant genes exhibit potential as novel biomarkers for therapeutic applications. These findings clarify the pathogenic mechanisms of SUMOylation in LF and establish a foundation for the development of innovative therapeutic targets and diagnostic markers, thereby aiding in the prevention and treatment of LF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.